hUCMSC-Exos alter renal injury markers, gut microbiota, and `NLRP3` inflammasome signaling in IgA nephropathy mice
Background
IgA nephropathy (IgAN) is the most prevalent primary glomerulonephritis globally and a leading cause of end-stage kidney disease, yet effective disease-specific therapies remain scarce. Current treatments often fall short in addressing the underlying pathology. Growing evidence points to gut microbiota dysbiosis and aberrant innate immune activation, particularly involving the NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome pathway, as key drivers in IgAN pathogenesis. This study investigated whether human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) could modulate these critical parameters in IgAN.
Study Design
Researchers isolated hUCMSC-Exos and administered them to an IgAN-like mouse model. The study assessed renal function, histopathological changes, and systemic inflammatory markers in these mice. Gut microbiota composition was meticulously analyzed using 16S rRNA sequencing, and exploratory microbial co-occurrence networks were constructed to identify key microbial interactions. In vitro, podocytes stimulated with galactose-deficient IgA1 (Gd-IgA1) were exposed to exosomes to evaluate inflammasome-related markers. Additionally, transcriptomic data from human IgAN glomeruli (GSE93798) were analyzed to explore inflammatory and immune-related gene signatures, providing translational context.
Results
Administration of hUCMSC-Exos was associated with significant changes in renal injury markers in the IgAN-like mice, alongside notable alterations in their gut microbial composition. Microbiome analysis revealed a beneficial shift toward a microbial profile more closely resembling that of control animals. This shift included the enrichment of specific bacterial taxa, such as Anaerostipes, Dorea, and Ruminococcus, which have previously been linked to gut metabolic homeostasis in other cohorts. These identified taxa showed strong correlations with indicators of renal dysfunction and various inflammatory markers, and were pinpointed as hub taxa within an exploratory co-occurrence network, suggesting their central role in the observed effects. > Transcriptomic analysis of human IgAN glomeruli further supported these findings, revealing altered expression of NLRP3 inflammasome-related genes and components of the aryl hydrocarbon receptor (AhR)-related signaling pathway, indicating a modulation of inflammatory activity.
Key Findings
- hUCMSC-Exos were associated with changes in renal injury markers in IgAN-like mice.
- hUCMSC-Exos altered gut microbial composition, shifting it closer to control profiles.
- Enrichment of beneficial gut bacteria (Anaerostipes, Dorea, Ruminococcus) was observed.
- These enriched taxa correlated with improved renal function indicators and inflammatory markers.
- Human IgAN glomeruli showed altered
NLRP3inflammasome andAhRsignaling gene expression.
Why It Matters
This research highlights hUCMSC-Exos as a promising therapeutic strategy for IgA nephropathy, offering a multi-pronged approach that targets not only direct renal injury but also the underlying gut-immune axis dysregulation. By demonstrating an association with improved renal markers and a healthier gut microbiota profile, this study suggests a novel pathway to potentially restore gut metabolic homeostasis and dampen systemic inflammation in IgAN. The findings open avenues for exosome-based therapies to address the root causes of IgAN, moving beyond current symptomatic treatments. While preclinical, this work provides a strong rationale for further investigation into the clinical translation of hUCMSC-Exos, potentially leading to protocols that integrate gut microbiome modulation with direct anti-inflammatory effects for kidney protection.
iga nephropathy
exosomes
hucmsc-exos
kidney disease
gut microbiota
inflammation